Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice to meet you @blue_skies. The company was dropped on my desk by one of our equity research analysts. We have been conducting a significant amount of research (which includes gauging public sentiment about the company) to determine the investment potential and risk. Some initial points that come to mind:
* A troubled past and uncertain future, potentially an interest for activist investors
* Growth prospects but little pipeline development to substantiate and support that growth (we’d like to see substantial R&D investments for a company in this industry)
* BS and IS look fine, however, legal expenses were significant this past quarter
* We’ve been monitoring stock intraday action closely
* Our team has spotted some intraday trading anomalies in the Level 2 and Level 3
* We are working with forensic analysts to determine what this signifies
* We want to better understand the public sentiment about this stock
* We need to comprehend the outlook and plan in greater detail
* We would definitely expect and need to see additional information in quarterly releases regarding “partnerships”, pipeline, etc.
* The management’s plan lacks specificity that would allow for firms in AM, IB, or CM to make more informed investment decisions
* The company seems to meet some, but not all uplist requirements. We will have to see what exchange they are interested in
The next quarter report will be an opportunity to more accurately judge the firm’s prospects.
@hfmanager - nice to see you on the REPR board. How did you hear about the company? Any thoughts about REPR as an investment?
I like the outside the US opportunity. That looks like a solid opportunity for significant growth.
Uplisting - I have seen some speculate that September 10th is a timeframe for potential uplisting - something to do with trading 90 days over $2.
I am waiting for that headline and hope to lighten my position into that strength. My position here is very large, just looking to pull some risk off.
I lik e he risk section as I think all, but the litigation, can be discounted, at this point. The activist shareholders must be tickled pink.
We even have momentum on the litigation.
any thoughts on the report?
If you copy/paste that link it should work.
Craig Hallum Update From Yesterday
file:///C:/Users/csiri/AppData/Local/Packages/Microsoft.MicrosoftEdge_8wekyb3d8bbwe/TempState/Downloads/REPR%20-%20Craig%20Hallum%209-9-19%20(1).pdf
Xembiy is only been approved in U.S. Other markets likely to follow. In a razor/razor blade model the razor blades for RMS are needle sets and tubing. These high profit items will grow exponentially through 2020 with a major impact on the company bottom line.
Question? Will RMS be able to meet demand? In the Q3 financials look at the inventory numbers compared to previous quarters.
Xembify® is Grifols’ first 20% SCIg for the treatment of PIDD (1)
§ Grifols plans Q4 2019 U.S. launch, working to obtain
approvals in Canada, Europe and other global markets (1)
§ We view this as a positive development for RMS Medical,
patients, and the industry
§ Approval should help address Ig supply chain constraints
and expand market opportunities
§ We see a low-risk of cannibalization to Hizentra®
§ Collaborating with pharmaceutical companies is a primary
component of RMS Medical’s Strategic Plan
https://d1io3yog0oux5.cloudfront.net/_2f9331a575b029ed6973d4ed07f75ecb/rmsmedicalproducts/db/351/2392/presentation/REPR+Q2+2019+Investor+Call.pdf
page 11
my post should have read "government partnership" my bad
https://d1io3yog0oux5.cloudfront.net/_2f9331a575b029ed6973d4ed07f75ecb/rmsmedicalproducts/db/295/2394/pdf/Canaccord+Conference+Slides+August+2019.pdf
page 19
Blue Skies
Where was that mention of government contracts?
Plenty of upside with this tiny float and clearly with the company buying shares, the sky is the limit...
@MWM - I see more upside.
Uplisting to a major exchange coming. This will bring additional visibility.
Two of three lawsuits settled favorably. Less legal expenses going forward. Strong incentive for EMED to settle.
Manufacturing efficiencies kicking in.
Look for product refinement and new product introductions as a result of a focused R&D program.
Sales of pumps and needle sets supporting Grifols’ SubQ Xembify will begin in fourth quarter and ramp up through next year. Possible bump in Q4 sales for Grifols’ Xembify subQ product launch??
Thank you for that. That puts, theoretically, the available shares below 20,000,000 by my estimation. Of course everyone has a price.
@Jliver - The former CEO, Andrew Sealfon owned approximately 8 million shares.
First light management bought some and now owns almost 7 million.
https://www.nasdaq.com/symbol/repr/ownership-summary
I agree with you that the large share holders are looking for more the $6/share. As RMS market presence increases it becomes a more desirable take over target.
More analysist will come on board when company uplists.
The current quarter will be negatively impacted by legal expenses. But those are mostly behind us.
Pettigrew teases investors with the bullet point "government contracts".
Today's Action
I think you may continue to see bull runs, like todays, on REPR given the current share allotment. These numbers are not meant to be exact, just to show how low the float is. Uplisting the next potential catalyst to draw buyers.
REPR has 38 million shares in the float - MANKO owns 12 million, various insiders own an additional 2 million. That number may be higher but I am lazy and whatever more exact number I find will have no impact on my position.
So you have a stock of about a 25 million (maybe less) float with one analyst covering - whose clients loaded up around $2-$2.50 and maybe higher. You have Manko with his huge position. I don't think he bought 12 million shares of this stock to try and get out at $4 or even $6.
He is likely looking for a lot more.
You have the Craig Hallum clientele who are likely not looking to sell as, just like me, the story is one that is easy to understand and is playing out perfectly.
New Management
"New" product in the sense that the marketplace is moving right towards REPR.
Run this through CANSLIM and you go 7 for 7 in my opinion. One could argue the C for current quarterly earnings is not their yet but they are moving in right direction per revenues. And the 60-70% margins will produce profit sooner rather than later.
@Jliver maybe the question about being reimbursed for legal fees can be raised and answered at the Craig Hallum conference today. There has to be a case history and precedents addressing the situations such as what RMS is in. If nothing else it will be a talking point between RMS and EDEM.
Idk about getting reimbursed legal fees.
I am more interested in seeing an updated report from Craig Hallum after they meet with the company. Hopefully REPR gives an update on Hizentra numbers and some indication on expectations for Xemblify.
I suspect the analyst is itching to up his price target (from $5.50) but will need some ammo to justify it
Craig Hallam note this morning.
Interesting note on meeting with company this week. I copy/pasted this from a micro cap club I belong to.
EPR* – The Southern District of New York Court announced on Friday that RMS won its lawsuit vs. EMED and dismissed the case. Alex Nowak notes there were three original lawsuits under old management in Texas, California and New York. The Texas case was resolved June 27th, New York was resolved Friday and California remains the final outstanding case. In particular, the NY case drove the majority of the legal spend, which amounted to $1.6M in 1H19. Alex points out legal spend should decline 2H19 with the dismissal, which is important as REPR only has $4M in cash. Craig-Hallum will be hosting management meetings in Minneapolis tomorrow and will be listening for an update on the legal efforts + business progress with Hizentra and Xembify. Alex rates REPR shares a Buy.
Lets make some money.
Big savings in legal fees, especially in fourth quarter.
Do you see RMS getting reimburses for legal fees?
Note - the NY case was dismissed with prejudice. This means its a final judgement and EMED has very few additional legal options!!! YAY
A dismissal with prejudice is dismissal of a case on merits after adjudication.The plaintiff is barred from bringing an action on the same claim. Dismissal with prejudice is a final judgment and the case becomes res judicata on the claims that were or could have been brought in it.
Damn, Dude, you’re quick.
There is one more case between RMS and EMED in CA. Given the outcomes in Texas and now NY, the likelihood is the that CA case will be follow suit. The pressure for EMED to settle increases exponentially with two strikes against them.
BIG savings in legal expenses. Last quarter RMS had over a million dollars of legal fees. Look for RMS to seek reimbursement for some if not all of the legal fees???
https://ir.rmsmedicalproducts.com/press-releases/detail/43/rms-medical-products-receives-another-favorable-court-ruling
CHESTER, N.Y.--(BUSINESS WIRE)-- Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS Medical” or “the Company”) today announced that on August 30, 2019 the United States District Court for the Southern District of New York (Case No. 1:18-cv-05880-LGS) issued a decision granting RMS Medical’s motion for summary judgement of non-infringement against EMED Technologies (“EMED”) U.S. Patent 9,808,576 (“576 Patent”) and dismissed the case with prejudice.
On November 7, 2017, EMED filed this case in the United States District Court for the Eastern District of Texas claiming patent infringement of the ‘576 Patent by the Company’s needle sets and seeking unspecified monetary damages. The case was later transferred to the United States District Court for the Southern District of New York and is one of several pending between RMS Medical and EMED.
“We are very pleased with the decision of U.S. District Court for the Southern District of New York, which confirms our belief that EMED’s infringement claim was without merit,” said Don Pettigrew, President and CEO of RMS Medical. “This ruling is the second consecutive favorable judgement that we have received regarding our ongoing litigation with EMED.”
On June 28, 2019, the United States District Judge for the Eastern District of Texas dismissed with prejudice EMED’s case on an earlier issued patent against RMS Medical and awarded court costs to RMS Medical. Subsequent to the Texas ruling, RMS Medical authorized its legal counsel to pursue recovery of legal fees from EMED associated with the Texas case.
Correction
that's $3.10 on the 10 day moving average
The one day reversal sets up the first technical negative in months. It’s on my mind but it was not on big volume which is good.
I am very focused on the 10 week moving avg which is right at $3. Important to stay above that.
The stock has definitely changed character here the last few trading days.
60k shares by 10:00 AM. Unussual! Down twenty-two cents.
The uplisting will be uplifting ;)
I prefer the slow grinding action on way up.
Hopefully we can close $3.55 plus for the week.
I have to be careful getting too wrapped up in the daily stock action.
This is a 300 million dollar company, at least, trading at 150 million or so. That’s what I need to keep on mind.
Great call.
Uplisting coming sooner then later?!
Technically
Stock looks ready to move above recent highs. Could jump to $3.60-3.76 short term.
Q2 2019 Highlights
Net sales rose 18.8% to $5.3 million. Second quarter in a row of record earnings. Expect earnings growth to accelerate as Grifols Xembify sales beginning to kick in during 2020. Management believes Xembify sales to be additive and will not cannibalize existing sales.
Gross margin improved to 65.0% Expect gross margins to continue improving with future sales growth and production efficiencies. Production efficiencies are like an annuity that keep paying benefits quarter after quarter.
The company has no debt and $3.8 million of cash and cash equivalents.
The above are a few of the reason I see this as a safe growth stock scenario.
Do your own DD.
There was some personal animosity between Sealfon and the owner of EMED. Maybe this is tinging the EMED's business decision.
I read this last night. While they explored settlement it would appear unlikely. REPR seems to win each court case and EMED doesn't appear willing to face reality.
Looking forward the uplisting. this would be uplifting to the stock :)
Hope to see that this quarter.
a more complete explanation of the legal proceedings can be found on pages 9-11 of the 10q.
Company not very forthcoming on guidance, other indications etc. Not unusual for such a small company.
I see the company as doing a good job of honestly managing investor expectations given the time window. They told stockholders to expect to see continued high legal expenses.
I would have liked a more in depth answer on the Grifols/Xemblify question.
My understanding is that sales to Grifols will start in the fourth quarter and will accelerate through 2020. A better sense of the projected numbers will come into focus later this year. Maybe something will be said in the next CC.
I was hopeful the legal fees would be minimized for rest of year. Company indicated otherwise.I’m wondering if a reasonable settlement (if possible) would be best way to go. I have zero knowledge of the complexities of the case etc. Me too. I see RMS as taking a very controlled measured approach. The company received a favorable judgement in Texas. RMS is playing from a strong hand and they know it! .
Plan on holding this long term as the story is solid. My largest position (MJCO, BMRA) Agreed. Strong growth, no debt, in expanding markets, good management team up-listing expected soon. I see this as a growth stock with minimal risk
Encouraged by bounce, so far, directly off the 10 week moving average.
Not unreasonable for this to consolidate for some time after huge % move. Agreed nice bounce indicating investors are looking past the short term legal expenses.
Of course I’d prefer a quick move to $4.50 :$ Think double digits
My reaction after the call.
Company not very forthcoming on guidance, other indications etc. Not unusual for such a small company.
I would have liked a more in depth answer on the Grifols/Xemblify question.
I was hopeful the legal fees would be minimized for rest of year. Company indicated otherwise.
I’m wondering if a reasonable settlement (if possible) would be best way to go.
I have zero knowledge of the complexities of the case etc.
Plan on holding this long term as the story is solid. My largest position (MJCO, BMRA)
Encouraged by bounce, so far, directly off the 10 week moving average.
Not unreasonable for this to consolidate for some time after huge % move.
Of course I’d prefer a quick move to $4.50 :$
uplifting - legal fees - government contracts
I believe, from the investment community perspective, that the uplifting and the totality of the RMS story will over shadow the short term large legal expenses?
Craig -Hallum will post an update shortly.
The company continues to mention government contracts in slide presentations but does not expand it??
I heard and noticed that also.
Do you have any other reactions.
Uplifting
sooner rather than later. Per CC.
Unfortunately the legal costs are not going to subside for the calendar year. Per CC.
Largest position.
This is another IHUB posters post. It is beautifully written.
Being a persistent pessimist is an easy road. An innovative and growing company will always encounter roadblocks and hurtles as it grows. It’s the natural progression in a company’s life cycle. But a pessimist will always say they were right and told us so when a roadblock/hurdle is encountered. It’s easy to focus on the negatives; they will always come. Moreover, these folks don’t have the courage to acknowledge positive outcomes along the way. In their minds it’s good to be right since negatives will happen; it’s a safe place to reside. Yet, when company success finally does come they change their minds saying the company has turned it around. It’s such an easy existence. It requires no commitment, very little integrity and since they dont have go out on a limb until success is firm in hand, zero loyalty.
Big,
I would like to listen to the CC tomorrow morning and hear what the management says.
I have been buying shares at this level.
i can not get by the size of the legal costs this quarter. To my mind it casts a shadow over everything else. say good bye to $3 for a while. Will be interested in what the Craig-Hallum analyst says.
Wondering why you think this casts a shadow? The court ruled in their favor in July, so barring new legal issues, legal costs should drop dramatically going forward.
bought a few shares today.
Earnings come out after close Tuesday
CC Wednesday morning
hoping to see $5.1 to $5.25 million in sales
expecting $500k legal fees mostly associated with lawsuit
will be watching R&D dollars, patent expenses, gross margins 63%?
curious about super26, and strategic partnerships
dreaming of $.02/share earnings but unlikely with the current legal fees.
Expect to see $.01share earnings
wonder what company plans on doing with res-q-vac?
management team filled out - kind of early but lets see how they are doing??
anyone care to speculate what the quarter financials will bring?
I see this quarter and CC as a coming out party. The recent court rulings provide the incentive to settle the expensive litigation. And do so giving RMS the upper hand. The super26 is starting to be marketed. Craig-Hallum cam out with a nice write of the company. I suspect others are watching RMS. The management team is complete. The marketing strategy of forming early on partnerships with pharma is working.
RMS Medical Products Schedules 2019 Second Quarter Financial Results and Conference Call
CHESTER, N.Y.--(BUSINESS WIRE)-- Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced that it will release its financial results for the second quarter and six months ended June 30, 2019 after the close of the financial markets on Tuesday, August 6, 2019. Management will host a conference call on Wednesday, August 7, 2019 at 9:00 am ET to discuss the results and business activities.
Interested parties may participate in the call by dialing:
(877) 407-9753 (Domestic) or
(201) 493-6739 (International)
Webcast registration: Click Here
Following the live call, a replay will be available for six months on the Company's website, www.rmsmedicalproducts.com, under "Investor Relations."
https://ir.rmsmedicalproducts.com/press-releases/detail/41/rms-medical-products-schedules-2019-second-quarter
welcome! always rooting for good shareholders who are patience and deserve to be rewarded!
REPR
Followers
|
67
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2463
|
Created
|
09/18/00
|
Type
|
Free
|
Moderators |
You may have heard of Repro Med Systems, Inc. That’s us! Today, we are operating as RMS Medical Products, a leading developer and manufacturer of medical devices and supplies. The company was incorporated in March, 1980 and is now publicly traded . Our stock symbol is REPR.
Worldwide, RMS Medical Products drives healthcare inspiration – in the minds of our patients, our employees, our customers and our shareholders – to give everyone greater freedom for living. We design and manufacture safe, affordable medical devices to make quality healthcare a reality for everyone.
We focus on home and specialty infusion solutions, emphasizing responsive problem-solving for our customers, and careful consideration for the patient experience. Our primary products are the FREEDOM60® and FreedomEdge® DynEQ Infusion Systems, RMS Precision Flow Rate Tubing™, HIgH-Flo Subcutaneous Safety Needle Sets™ and RES-Q-VAC® Hand Held Medical Suction.
We are passionate about helping people with our reliable medical devices made at our HQ in Chester, NY (USA). Our products, as well as product support, are offered worldwide by RMS and through a global network of distributors and service providers.
RMS is excited to expand into new markets with innovative, more technical products. We look forward to productive partnerships with people and companies who share our vision and can help us effectively deliver our value promise to stakeholders in our industry.
Web Site
http://www.repro-med.com
Main Products
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |